tvardiTherapeutics
Nasdaq: TVRDSugar Land, TX

01 · Oral STAT3 inhibitors

Oral medicines
for a target once
thought undruggable.

Small-molecule inhibitors of STAT3, where cancer, fibrosis & chronic inflammation converge.

Figure 1STAT3 · Dual mechanism
STAT3 INTRINSIC Tumor / fibrotic cell EXTRINSIC Immune cell
Clinical STAT3 programs
2 TTI-101 · TTI-109

02 · Phase 2 REVERT IPF

Clinical evidence
in idiopathic
pulmonary fibrosis.

Oral STAT3 inhibitor TTI-101 versus placebo, measured at week 12 of the Phase 2 REVERT trial.

Figure 2Fibrosis score decrease · Wk 12
5% 0 2.4% 9.4% PLACEBO TTI-101 Phase 2 REVERT IPF · per company disclosures
FDA designations
Orphan + Fast Track Hepatocellular carcinoma (HCC)

03 · TTI-109 · Phase 1

Equivalent
exposure, improved
tolerability.

TTI-109, a phosphate prodrug of TTI-101, converts to the active drug in under 2 hours.

Figure 3TTI-109 → TTI-101 → STAT3
TTI-109 Prodrug <2 hrs TTI-101 Active drug STAT3 Target TTI-101-equivalent exposure in Phase 1
Tolerability
0.46 vs 3.35 days Diarrhea events, avg. TTI-109 vs TTI-101

04 · Pipeline & catalyst

Phase 2 HCC
topline expected
H2 2026.

TTI-101's Phase 2 trial in hepatocellular carcinoma spans monotherapy and combination.

Figure 4Clinical path · Catalyst
EXP. H2 2026 TTI-101 Oral STAT3 inhibitor PHASE 1 Established PHASE 2 HCC NCT05440708 REVERT IPF Phase 2 data TOPLINE Phase 2 HCC Expected timing per company disclosures
Cash & short-term investments
$25.0M As of Mar 31, 2026
Clinical-stage biopharma · HCC · IPF
Read the Investor Overview
Forward-looking statements · verify figures in SEC filings